Flag of the European Union EU Clinical Trials Register Help

Clinical trials for P site

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    225 result(s) found for: P site. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000058-24 Sponsor Protocol Number: Connect&Go Start Date*: Information not available in EudraCT
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.
    Medical condition: Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005340-24 Sponsor Protocol Number: SONIA1 Start Date*: 2013-02-26
    Sponsor Name:University of Liverpool (UniLiv)
    Full Title: An international, multicentre, randomised, open-label, no-treatment controlled, parallel group, dose-response study to investigate the effect of once daily nitisinone on 24-hour urinary homogentisi...
    Medical condition: Alkaptonuria (AKU) - a serious, autosomal recessive, multisystem disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004321-16 Sponsor Protocol Number: CCOA566A2417 Start Date*: 2017-08-31
    Sponsor Name:Novartis Pharma AG
    Full Title: A study of the effects of Coartem, Malarone and artesunate-mefloquine on auditory function in patients 12 years of age or older with acute uncomplicated P. falciparum malaria
    Medical condition: This study assessed the effects of artemether-lumefantrine on the auditory nerve pathway as assessed by Auditory Brainstem Response (ABR) and audiometric testing in acute uncomplicated Plasmodium f...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016590-15 Sponsor Protocol Number: CTBM100C2304 Start Date*: 2009-12-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infection...
    Medical condition: Lung colonisation with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    14.1 100000004862 10068292 Pseudomonas colonization LLT
    14.1 100000004862 10068297 Pseudomonas colonisation LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000714-65 Sponsor Protocol Number: PHAGOBURN Start Date*: 2015-06-24
    Sponsor Name:Pherecydes Pharma SA
    Full Title: Evaluation of phage therapy for the treatment of Pseudomonas aeruginosa wound infections in burned patients (Phase I-II clinical trial)
    Medical condition: P. aeruginosa infected wound in burned patients.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004461-85 Sponsor Protocol Number: CCOA556B2401 Start Date*: 2016-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic tre...
    Medical condition: This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on the number of cl...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002166-39 Sponsor Protocol Number: NL44924.100.13 Start Date*: 2013-12-19
    Sponsor Name:Sint Antonius Hospital
    Full Title: Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status
    Medical condition: Immune response to pneumococcal vaccination in patients after community acquired pneumonia with Streptococcus pneumoniae
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10071915 Vaccination site bleeding LLT
    16.0 100000004863 10046860 Vaccination adverse reaction LLT
    16.0 100000004867 10069488 Vaccination site paresthesia LLT
    16.0 100000004867 10069630 Vaccination site edema LLT
    16.0 100000004863 10059078 Vaccination related malaise LLT
    16.0 100000004865 10046859 Vaccination LLT
    16.0 100000004867 10069485 Vaccination site stinging LLT
    16.0 100000004867 10069631 Vaccination site tenderness LLT
    16.0 100000004867 10069473 Vaccination site hematoma LLT
    16.0 100000004867 10069486 Vaccination site discoloration LLT
    16.0 100000004867 10069487 Vaccination site hemorrhage LLT
    16.0 100000004863 10067538 Inappropriate route of vaccination LLT
    16.0 100000004867 10069483 Vaccination site burning LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002551-15 Sponsor Protocol Number: 8951-CL-5201 Start Date*: 2019-02-05
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatmen...
    Medical condition: First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001205-41 Sponsor Protocol Number: VIPER–AMI Start Date*: 2015-01-09
    Sponsor Name:Sociedade Portuguesa de Cardiologia
    Full Title: VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction – A single centre, randomized, parallel-group, double-blind clinical trial, for assessing the effectiveness...
    Medical condition: ST Elevation Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    17.1 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005446-35 Sponsor Protocol Number: AI447-028 Start Date*: 2012-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment- Naive Subje...
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) AT (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004391-34 Sponsor Protocol Number: VAC072 Start Date*: 2019-05-24
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of adjuvanted R21, administered in different dose schedules in healthy UK volunteers.
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-020936-21 Sponsor Protocol Number: VOSG-P-319 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Consumer Health S.A.
    Full Title: A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with ...
    Medical condition: Acute blunt soft tissue injuries/contusions of the limbs
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050584 Contusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000680-24 Sponsor Protocol Number: POSTrct_ORTGH Start Date*: 2012-05-25
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Pain management after operative treatment of extremity fractures, a randomized clinical trial
    Medical condition: Patient satisfaction with pain relief and pain intensity (Numeric Rating Scale) will be investigated. Also to find predictors we will investigate: age, sex, trauma-site, fracture type, AIS score, ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10024956 Lower limb fractures HLT
    19.1 100000004865 10036236 Postoperative pain relief LLT
    19.1 100000004848 10033762 Paracetamol LLT
    17.1 100000004859 10046292 Upper limb fractures HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000290-20 Sponsor Protocol Number: 204889 Start Date*: 2017-09-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or wi...
    Medical condition: Healthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005059-19 Sponsor Protocol Number: C0921062 Start Date*: 2021-03-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10076062 Meningococcal immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006017-38 Sponsor Protocol Number: RGB-14-101 Start Date*: 2021-07-13
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) CZ (Completed) HU (Completed) BG (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004771-36 Sponsor Protocol Number: IC43-202 Start Date*: 2012-01-19
    Sponsor Name:Valneva Austria GmbH
    Full Title: A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.
    Medical condition: Nosocomial Pseudomonas aeruginosa infections in mechanically ventilated ICU patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10061471 Pseudomonas infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012076-26 Sponsor Protocol Number: 20080560 Start Date*: 2009-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivati...
    Medical condition: Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy (ADT) for Non-metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065687 Bone loss LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) CZ (Completed) PL (Completed) LV (Completed) GR (Completed) SK (Completed) BG (Completed) HU (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2015-004596-72 Sponsor Protocol Number: EXCALIBUR Start Date*: 2016-04-06
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration resistant prostate cancer (mCRPC) patients with visceral disease
    Medical condition: metastatic prostate cancer resistant to castration with visceral disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002153-30 Sponsor Protocol Number: MO40628 Start Date*: 2018-10-24
    Sponsor Name:Roche Farma S.A.(Soc Uni) que realiza el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in ...
    Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 07:51:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA